Who is sponsoring NCT02614456?

NCT02614456 is sponsored by Fox Chase Cancer Center.

What drugs are being tested in NCT02614456?

Interventions in NCT02614456: interferon-gamma and nivolumab.

What condition does NCT02614456 study?

NCT02614456 studies Advanced Solid Tumors.

Is NCT02614456 still recruiting?

NCT02614456 is currently completed. Last updated 29 November 2019.

Last reviewed 2019-11-29 · How we verify

NCT02614456

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors

Completed Phase 1 Last updated 29 November 2019

What this trial tests

Phase 1 trial testing interferon-gamma and nivolumab in Advanced Solid Tumors in 26 participants. Completed in 12 June 2019.

Timeline

11 December 2015

Primary endpoint
12 June 2019

12 June 2019

Quick facts

Lead sponsor	Fox Chase Cancer Center
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	26
Start date	11 December 2015
Primary completion	12 June 2019
Estimated completion	12 June 2019
Sites	1 location across United States

Drugs / interventions tested

interferon-gamma and nivolumab — full drug profile →

Conditions studied

Advanced Solid Tumors — all drugs for Advanced Solid Tumors →

Sponsor

Fox Chase Cancer Center — full company profile →

Who can join

18 and older, any sex, with Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase I study of combination immunotherapy with IFN-γ and the PD-1 inhibitor nivolumab in patients with advanced solid tumors who have progressed on at least one prior systemic therapy, which may include prior immunotherapy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Roles of IFN-γ in tumor progression and regression: a review.
Jorgovanovic D, Song M, Wang L, Zhang Y. · · 2020 · cited 973× · PMID 33005420 · DOI 10.1186/s40364-020-00228-x
Genomic correlates of response to immune checkpoint blockade.
Keenan TE, Burke KP, Van Allen EM. · · 2019 · cited 367× · PMID 30842677 · DOI 10.1038/s41591-019-0382-x
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
Wu M, Huang Q, Xie Y, Wu X, et al · · 2022 · cited 336× · PMID 35279217 · DOI 10.1186/s13045-022-01242-2
Interferon gamma in cancer immunotherapy.
Ni L, Lu J. · · 2018 · cited 274× · PMID 30039553 · DOI 10.1002/cam4.1700
Targeting cytokine and chemokine signaling pathways for cancer therapy.
Yi M, Li T, Niu M, Zhang H, et al · · 2024 · cited 264× · PMID 39034318 · DOI 10.1038/s41392-024-01868-3
The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion.
Mojic M, Takeda K, Hayakawa Y. · · 2017 · cited 240× · PMID 29283429 · DOI 10.3390/ijms19010089
Cancer immunotherapy: it's time to better predict patients' response.
Pilard C, Ancion M, Delvenne P, Jerusalem G, et al · · 2021 · cited 145× · PMID 34112949 · DOI 10.1038/s41416-021-01413-x
The Interferon-Gamma Paradox in Cancer.
Zaidi MR. · · 2019 · cited 137× · PMID 30388040 · DOI 10.1089/jir.2018.0087

Verify or expand the search:

Other recruiting trials for Advanced Solid Tumors

Currently open trials in the same condition.

NCT07504445 — Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07589530 — Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07360314 — Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07414316 — A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. · EARLY_PHASE1 · recruiting
NCT07222969 — A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Fox Chase Cancer Center trials

Trials by the same sponsor.

NCT07455032 — Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous · Phase 1 · recruiting
NCT07221942 — Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma · Phase 2 · recruiting
NCT07221058 — Adaptive Radiation Boost for Rectal Cancer · Phase 1 · recruiting
NCT07167446 — Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy · EARLY_PHASE1 · recruiting
NCT07219303 — Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02614456 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fox Chase Cancer Center
Last refreshed: 29 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02614456.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing